Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

By sjmartinez • April 14, 2024

Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open. 2024 Apr 12;10(2):e003912. doi: 10.1136/rmdopen-2023-003912. PMID: 38609322.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics, tumor necrosis factor inhibitors

Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead

Tang AB, Lewsey SC, Yancy CW, Heidenreich PA, Greene SJ, Allen LA, Jessup M, Bolles M, Rutan C, Navar N, Thomas K, Fonarow GC. Get[...]

Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United States Federally Qualified Health Centers

Zhao MY, Aaronson MRM, Singh V, De Silva SR, Badiee J, May FP. Worsening Racial and Ethnic Disparities in Colorectal Cancer Screening Rates in United[...]

Validating the Sino-Nasal Outcome Test (SNOT-22) in comparison to the Sino-Nasal 5 Questionnaire (SN-5) in a pediatric population

Cheng MY, Rodriguez DR, Rubio A, Jackson NJ, West AN. Validating the Sino-Nasal Outcome Test (SNOT-22) in comparison to the Sino-Nasal 5 Questionnaire (SN-5) in[...]